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INTRODUCTION 
 
Osteo-arthritis is a commonest among 
various articular disorders.  It is chronic 
affection of synovial joints and is related to 
ageing process of tissues.  It is not a single 
disease. Rather it is the end result of a 
variety of patterns of joint failure.  To a 
greater or lesser extent it always 
characterized by both degeneration of 
articular cartilage and simultaneously 
proliferation of new bone, cartilage and 
connective tissue. 
 
Osteo – arthritis is classified as primary if 
the aetiology is unknown and secondary 
when degenerative joint changes occur in 
response to a recognizable local or systemic 
factor.  In Ayurveda the disease entity 
Sandhivata has been described in reference 
to the description of various pathological 
conditions caused by vata under vatavyadi.  
Charka has described the swelling in 
Sandhigata vata resembling air filled bag on 
touch with pain and restricted movement.   
Further Sushruta has added that along with 
swelling and pain there is complete 
disorganization of joints leading to severe 
disabilities. 
 
Besides the above diseases some symptoms 
like joint pain, loss of function and strength 
of the joint and loss of flesh etc are also 
manifested when aggravated vayu located in 
majja and Asthivaha srotas. 
 
There are innumerable descriptions of 
medications covering various routes of 
administration and their actions are not yet 
evaluated with the advancement of the 
knowledge.  Regarding this disease and its 
management scientists are trying to ascertain 
the positive source of remedies for many 
ailments including Sandhivata still posses 
and unsolved process to be handled 
carefully. 
 
So the study entitled “Clinical evaluation of 
Nirgundi Taila in the management of 
Sandhivata” was planned to carry out. 
 
MATERIALS AND METHODS: 
 
This is a case control clinical study and 
comparison with known standard drug, 
carried out at P.G. Department of 
Kayachikitsa, Gopabandhu Ayurveda 
Mahavidyalaya, Puri during the period from 
December 1997 to September 1998.  The 
cases resembling sandhivata reported at the 
out patient department at GAM Puri opted 
for under trial were screened and among 
them 32 cases were registered for the 
present study availing the criteria of 
selection. 
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SELECTION OF CASES : 
 
The selected cases were asked to submit 
their written consent.  The selection was  
 
 
based on availability of following cardinal 
clinical features. 
 
i.  Age above 40 years in either sex. 
ii.  Swelling of the joints 
iii. Stiffness of the joints 
iv. No pain on reset of the confined joint/joints 
v.  Loss of function of the joint/joints 
vi. Crepitus and small effusion. 
 
EXCLUSION CRITERIA: 
 
Patients having below 40 years of age, 
rheumatoid arthritis, infective arthritis, gout 
and other joint diseases, hypertension, renal 
pathology, diabetes, pregnancy, lacation, 
history of carcinoma, reduction of joints 
space on x-ray. 
 
STUDY DESIGN: 
 
No. of patients   : 32 
 
Trial group    : Group  -  I  - 12 cases 
        Group  -  II  - 12 cases 
 
Control group   : Group  -   III  -  08 cases 
 
Duration of study      : 28 days 
 
Drug  : Nirgundi Taila, Diclophenac Sodium. 
Dose  : For  Group I  -  Nirgundi Taila massage 20 ml. daily. 
    Group II  -  Nirgundi Taila 20 ml. for massage.  
     And  5  ml.  to  intake  daily. 
    Group III  -  Diclophenac Sodium 50 mg thrice daily. 
 
DIET AND REGIMEN ADVISED: 
 
The patients were advised to take newly 
produced til and wheat, one year old Sali 
and sasthi rice, vegetables like snake guard, 
brinjal, drumstick, garlic etc.,  meat juice of 
aquatic and domestic animals, fruits like 
dadima-mango, riped palmex, greens as 
ganda prasarini, gokshura etc., milk of cow 
goat and buffalo. 
 
The patients were also advised to avoid 
chinta, ratrijagarana, vegadharana, 
anasana etc., rice of bamboo, koda, water of 
river and pond, green gram, black gram, 
milk of donkey, dried meat, traveling on 
horse and elephant, walking, sexual 
intercourse and completely bed rest should 
be avoided. 
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PREPARATION OF TRIAL DRUG: 
 
The drug was prepared according to the 
Principal of Ayurvedic formulary of India 
and ingredients were taken as described in 
Vata Vyadhi chapter of Charaka Samhita. 
 
CLINICAL ASSESSMENT OF CASES: 
 
The clinical assessment includes noting of 
changes of the following subjective and 
objective signs and symptoms as mentioned 
in assessment scale. 
 
SUBJECTIVE SYMPTOM: 
 
Pain (Sandhi sula) – As defined under 
assessment scale. 
 
OBJECTIVE SYMPTOMS: 
 
a.  Stiffness      -  As defined under assessment scale. 
b.  Tenderness    -  As defined under assessment scale. 
c.  Range of Movement  -  As defined under assessment scale. 
d.  Walking time    -  As defined under assessment scale. 
e.  Crepitation    -  As defined under assessment scale. 
 
TOXICITY PROFILE: 
 
During the course of trial attention was 
given to note the development of any 
adverse effects, intolerance, toxicity, etc. 
 
ASSESSMENT SCALE: 
 
The following pattern of Assessment Scale 
was made for estimation of percentage of 
relief.  PAIN: Pain is a subjective feeling, 
hence an accurate measurement of pain 
become very difficult.  Response of 
stimulation of pain also differs from person 
to person.  However for the present study 
following gradation of scales was adopted 
for measuring the intensity of pain. 
 
G – 0      Absent or no pain 
 
G I – Mild    Perception of pain, but not interfering his normal activity 
 
G II – Moderate  Perception of pain, interfering normal activities and looking  
                                    painful. 
 
G III – Severe   Excessive pain, associated with painful cries, agoinising look and  
                                    interfered normal activities. 
 
RESTRICTED JOINT MOVEMENT: 
 
“HANTI DANDHIGATA SANDHIN” is 
the cardinal symptom of sandhivata hanti 
means loss of joint function.  Besides other 
functions clinically it is evidently found that 
FLEXION is the first movement to go off.  
For the present study flexion of joint was 
taken for restricted movement.  Gradation of 
the different joints as under. 
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     K n e e    H i p    S h o l d e r  S p i n e  
 
G 0  Normal range of flexion  130
0   90
0   90
0   5cm 
 
G  I  Mild     120
0-130
0 80
0-90
0  80
0-90
0  4cm-5cm 
 
G  II  Moderate    60
0-119
0  40
0-79
0  40
0-79
0  2cm-4cm 
 
G  III  Severe     0
0-59
0   0
0-39
0   0
0-39
0   0cm-2cm 
 
The range of joint movements were 
measured with the help of specially designed 
device for measuring the angles, the A side 
of apparatus was placed on the joint line 
which corresponds to 180 degrees, then B 
side of the apparatus was moved to the side 
of maximum possible joint movement.  Now 
the angle apparatus was measured with the 
help of a protractor. 
 
STIFFNESS :- (Early morning stiffness = EMS) 
 
Stiffness was recorded on the basis of duration of time and graded as under 
 
G    0    Absence of stiffness 
 
G I    Mild    30 min  
 
G II    Moderate  31 min to 60 min. 
 
G III    Severe    61 min and above. 
 
CREPITATION: 
 
Structural abnormally causes crepitus which 
is emphasized in criteria for measuring OA.  
Gradation scale for measuring crepitus as 
under :- 
 
G 0      Absent or no crepitus 
 
G I    Mild    Crepitus complained by patient but not felt on examination  
 
G II    Moderate  Crepitus felt on examination. 
 
G III    Severe    Crepitus felt and heard on examination. 
 
TENDERNESS: 
 
Tenderness was evaluated on the basis of standard criteria of “RAI” as under 
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G 0      Absent or no tender 
 
G I    Mild    Tender 
 
G II    Moderate  Tenderness and wincing. 
 
G III    Severe    Tenderness, wincing and withdrawal. 
 
WALKING TIME: 
 
Grading of walking speed for 20mts. 
distance without support.  For this purpose 
patients were asked to walk 20 mts distance 
in a straight line with maximum possible of 
speed.  The time taken to cover 20 mts were 
recorded with help of stop watch in seconds.  
Male patients were asked to wear underpants 
and female patients were asked to lift saree 
up to the knee joint and then walk with 
naked feet. 
 
G 0  Normal  20 mts. In 20 sec 
 
G I    Mild    20 mts. In 30 sec 
 
G II    Moderate  20 mts. In 40 sec. 
 
G III    Severe    20 mts. In 50 sec. 
 
(Patients with OA of knee, hip and spine 
were only included for walking time 
assessment.  Those with other joint 
affection, those who are bed ridden and 
those walking with the help of certain aids 
were excluded from this criteria of 
assessment). 
 
RESULT 
 
On assessment of result in trial group – 1 
after 14 days of treatment no patient got 
maximum improvement, 25% got moderate 
improvement, 33.33 % got mild 
improvement and no improvement was 
observed in 41.67% of cases.  But after 28 
days of treatment 8.33% patients got 
maximum improvement, 16.67% got 
moderate improvement, 66.67% got mild 
improvement and 8.33% got no 
improvement. 
 
In trial group – 2 after 14 days of treatment 
no patients were observed in maximum 
improvement.  16.67 % got moderate 
improvement, 41.67 % got mild 
improvement and another 41.67 % got no 
improvement.  After 28 days of treatment 
16.67% patients got maximum 
improvement, 41.67 % each got moderate 
and mild improvement respectively. 
 
In control group 87.5% of patients got 
maximum improvement and 12.5% got 
moderate improvement after a period of 14 
days treatment and after completion of 28 
days treatment 100% got maximum 
improvement. 
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From the above response it is evident that 
the response is elevated with pana  and 
Abhyanga treatment and it is comparatively 
more effective than other two groups.  The 
drug for pana and Abhyanga seems to be 
effective as balya, vatahara and  vedana 
stapaka. 
Comparatively the trial drug seems to be 
much more effective than control drug.  The 
reason may be due to trial drug having 
nutritive effect, so to get the maximum 
improvement it requires more duration of 
treatment and the possibility of reoccurrence 
of the disease is less. 
 
Control drug (diclophenac sodium) 
exhibited with shorter span of time limit 
involving certain risks like acidity, gastric 
discomfort etc.  The effect on the cardinal 
symptoms obtained through the control drug 
was not sustained and satisfactory.  It is for 
the reason that symptoms like pain could be 
controlled without any repairment to the 
bone surface.  Soon after withdrawal of drug 
there was appearance of the sign and 
symptoms again. 
 
TOXICITY: 
 
We could not observe any toxic effect of 
trial drug.  Only two patients were 
complaining of coated tongue and 
tastelessness for sometimes after intake of 
Taila.  In case of control group some 
patients were complaining of loss of appetite 
after 14 days of treatment. 
 
SUMMARY & CONCLUSION: 
 
It has been statistically analaysed that the 
application of drug -1 (Abhyanga) is 
significantly effective to reduce pain, 
stiffness, restricted movement, tenderness 
and walking time after 14 days of treatment.  
But after 28 days treatment it becomes 
highly significant.  In case of crepitation it 
was insignificant after 14 days treatment and 
becomes highly significant after 28 days of 
treatment. 
 
After 14 days of treatment in trial group- 2 
drug showed significantly effective to 
reduce all cardinal sign-symptoms and 
becomes highly significant after 28 days of 
treatment.  In case of crepitation it was 
highly significant after 14 days of treatment. 
 
In control group of effectives of the drug 
was highly significant after 14 days 
treatment. 
 
As trail drug has no toxic effect on every 
sign and symptoms it may be taken for 
better treatment for Sandhivata. 
 
MAJOR FINDINGS: 
 
Approximately 60% patients belonged to 
middle age groups (40-60 years) and 40% 
belonged to old age group.  The males were 
75% and females 25%. 
 
 
More than 80% of the patients used to take ruksha and sita ahara. 
Approximately 69% of patients were having krurakostha. 
More than 80% of the patients were having krusha and swabhavika akriti. 
Approximately 69% patients were having visamagni. 
Approimately 66% patients were having vata prakruti and vata nadi. 
 
The treatment for a period of 28 days could 
derive satisfactory improvement in most of 
the cardinal sign and symptoms observed 
among trial group – 1 and 2 patients. 
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Keeping in view of the relief status and 
percentage of recovery the trial drug can be 
accepted as a therapeutic regimen in case of 
Sandhivata.  However duration of more than 
28 days may be taken so as to obtain 
maximum benefit. 
 
Among the control group patient’s recovery 
was faster in all cardinal symptoms but 
sustainable. The disadvantage like acidity, 
abdominal discomfort were observed with 
the control drug.  There was relapse soon 
after the drug was withdrawn.  The Victims 
were observe with craziness for drug, which 
established the drug being unsuitable. 
 
The improvement obtained from massage 
and oral use of Nirgundi Taila was 
demonstrated more complementary and 
acknowledgeable than the massage alone. 
 
There is no apprehension left in prescribing 
the drug in case of Sandhivata  of various 
severity for a period of 28 days. 
 
The above treatment was demonstrated 
without any adverse effect or intolerance 
thus declared safe. 
 
THE CLINICAL AND STATISTICAL FINDINGS ARE AS FOLLOWS: 
 
TRIAL 
GROUP -1 
TRIAL 
GROUP – 2 
Control 
Group 
Sl. 
No. 
Clinical Assessment 
AT-14 AT-28 AT-14 AT-28 AT-14 AT-28 
1 Maximum 
Improvement 
00 01 00 02 07 08 
2  Moderate  Improvement  03 02 02 05 01 00 
3  Mild  Improvement  04 08 05 05 00 00 
4  No  Improvement  05 01 05 00 00 00 
 
The disease Sandhivata is not fatal but the 
working capacity of the individual is 
declined. 
 
It is concluded that snehana(Abhyanga and 
pana) has definite role on Sandhivata  to 
induce some benefits up to satisfaction. 
 
Though the drugs having this ingredient may 
not provide a miraculous change in the 
treatment of Sandhivata at present, the 
present work focuses on a basic data and 
documentation of ideas to the future 
researchers to try this drug in combination 
with internal medicines which may evolve 
more satisfactory recipe for the treatment of 
Sandhivata. 
 
Further study on the large number of 
patients is invited for the establishment of 
medicine for its wider use. 
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STATISTICAL ASSESSMENT 
For the purpose of statistical assessment the mean ± S.D. before treatment of each sign/symptoms has been 
compared with mean ± S.D. value after treatment.  Paired t-test is used for the purpose of test of significance.  The 
effectiveness of the drug is assessed through the P-value. 
 
Table No.1 
Showing Statistical analysis showing the effectiveness of T.D. (1) to different 
sign/symptoms. 
 
Sl. 
No. 
Sign/Symptoms Treatment Mean  ± 
S.D 
d.f. t-Value  P-Value  Remarks 
1 Pain  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11 3.93 
5.67 
<0.01 
<0.001 
Significant
Highly 
Significant
2 Stiffness  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11  3.39 
5.67 
<0.01 
<0.001 
Significant
Highly 
Significant
3 Restricted 
Movement 
B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11  3.39 
5.67 
<0.01 
<0.001 
Significant
Highly 
Significant
4 Crepitation  B.T. 
A.T. (14) 
A.T. (28) 
1.75 ± 0.72 
1.58 ± 0.49 
0.58 ± 0.49 
11  1.45 
10.56 
<0.05 
<0.001 
Significant
Highly 
Significant
5 Tenderness  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11  3.39 
5.76 
<0.01 
<0.001 
Significant
Highly 
Significant
6 Walking  Time  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11  3.39 
5.67 
<0.01 
<0.001 
Significant
Highly 
Significant
Tabulated t-values are as follows t1%11 = 3.11, t0.1%11 = 4.59, t5%11= 2.20 
 
 
Table No.2 
Showing Statistical analysis showing the effectiveness of T.D. (2) to different 
sign/symptoms. 
 
Sl. 
No. 
Sign/Symptoms Treatment Mean  ± 
S.D 
d.f. t-Value  P-Value  Remarks 
1 Pain  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11 3.93 
5.67 
<0.01 
<0.001 
Significant
Highly 
Significant
2 Stiffness  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11  3.39 
5.67 
<0.01 
<0.001 
Significant
Highly 
Significant
3  Restricted  B.T.  2.67 ± 0.47  11  3.39 <0.01  Significant
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Movement A.T.  (14) 
A.T. (28) 
2.08 ± 0.76 
1.5 ± 0.76 
5.67  <0.001  Highly 
Significant
4 Crepitation  B.T. 
A.T. (14) 
A.T. (28) 
1.75 ± 0.72 
1.58 ± 0.49 
0.58 ± 0.49 
11  1.45 
10.56 
<0.05 
<0.001 
Significant
Highly 
Significant
5 Tenderness  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11  3.39 
5.76 
<0.01 
<0.001 
Significant
Highly 
Significant
6 Walking  Time  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.47 
2.08 ± 0.76 
1.5 ± 0.76 
11  3.39 
9.63 
<0.01 
<0.001 
Significant
Highly 
Significant
Tabulated t-values are as follows t1%11 = 3.11, t0.1%11 = 4.44 
 
Table No.3 
Showing Statistical analysis showing the effectiveness of C.D to different sign/symptoms. 
 
Sl. 
No. 
Sign/Symptoms Treatment Mean  ± 
S.D 
d.f. t-Value  P-Value  Remarks 
1 Pain  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.48 
0.12 ± 0.33 
0 ± 0 
11 9.02 
 
<0.001 
<0.001 
Highly 
Significant
Highly 
Significant
2 Stiffness  B.T. 
A.T. (14) 
A.T. (28) 
2.67 ± 0.48 
0.12 ± 0.33 
0 ± 0 
11  9.02 
 
<0.001 
<0.001 
Highly 
Significant
Highly 
Significant
3 Restricted 
Movement 
B.T. 
A.T. (14) 
A.T. (28) 
2.62 ± 0.48 
0.12 ± 0.33 
0 ± 0 
11  9.02 
 
<0.001 
<0.001 
Highly 
Significant
Highly 
Significant
4 Crepitation  B.T. 
A.T. (14) 
A.T. (28) 
1.75 ± 0.66 
0.12 ± 0.48 
0 ± 0 
11  6.95 
 
<0.001 
<0.001 
Highly 
Significant
Highly 
Significant
5 Tenderness  B.T. 
A.T. (14) 
A.T. (28) 
2.62 ± 0.48 
0.12 ± 0.33 
0 ± 0 
11  9.02 
 
<0.001 
<0.001 
Highly 
Significant
Highly 
Significant
6 Walking  Time  B.T. 
A.T. (14) 
A.T. (28) 
2.62 ± 0.48 
0.12 ± 0.33 
0 ± 0 
11  9.02 
 
<0.001 
<0.001 
Highly 
Significant
Highly 
Significant
Tabulated t-values are as follows : t0.1%7 = 5.41 
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